The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The Prognostic Power of the NOD2 Genotype for Complicated Crohn's Disease: A Meta-Analysis
Abstract
OBJECTIVES: Crohn's disease is often purely inflammatory at presentation, but most patients develop strictures and fistulae over time (complicated disease). Many studies have suggested that nucleotide-binding oligomerization domain 2 (NOD2) mutations are associated with a varying but increased risk of complicated disease. An accurate and sufficiently powerful predictor of complicated disease could justify the early use of biological therapy in high-risk individuals. We performed a systematic review and meta-analysis to obtain accurate estimates of the predictive power of the identified mutations (such as p.R702W, P.G908R, and p.Leu1007fsX1008) in NOD2 for the risk of complicated disease. METHODS: An electronic search of MEDLINE, Embase, and Web of Science identified 917 relevant papers. Inclusion required specification of genetic mutations at the individual level and disease phenotypes by Vienna classification (inflammatory (B1), stricturing (B2), and fistulizing (B3)). A total of 49 studies met these criteria, which included 8,893 subjects, 2,897 of whom had NOD2 mutations. Studies were weighted by median disease duration. Studies not providing duration data were weighted at the level of the study with the shortest disease duration (3.9 years). RESULTS: The relative risk (RR) of the presence of any NOD2 mutant allele for complicated disease (B2 or B3) was 1.17 (95% confidence interval (95% CI) 1.10-1.24; P<0.001). P.G908R was associated with an RR of complicated disease of 1.33 (95% CI 1.11-1.60; P=0.002). NOD2 did not predict perianal disease (P=0.4). The RR of surgery was 1.58 (95% CI 1.38-1.80; P<0.001). There was substantial heterogeneity across all studies (I(2)=66.7%). On the basis of logistic regression of these data, the sensitivity of any mutation in predicting complicated disease was 36% and specificity was 73%, with the area under the receiver operating characteristic curve 0.56. CONCLUSIONS: The presence of a single NOD2 mutation predicted an 8% increase in the risk for complicated disease (B2 or B3), and a 41% increase with 2 mutations. Surgery risk is increased by 58% with any NOD2 mutation, whereas perianal disease was unchanged. The predictive power associated with a single NOD2 mutation is weak. The RR of any NOD2 mutations for complicated disease was only 17% across 36 studies. However, the presence of two NOD2 mutations had 98% specificity for complicated disease. These data provide insufficient evidence to support top-down therapy based solely on single NOD2 mutations, but suggest that targeted early-intensive therapy for high-risk patients with two NOD2 mutations might be beneficial, if prospective trials can demonstrate changes in the natural history in this subset of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Reitsma, J. B., Glas, A. S., Rutjes, A. W. S., Scholten, R. J. P. M., Bossuyt, P. M., & Zwinderman, A. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.02.022 · Cited by 3,369
The diagnostic odds ratio: a single indicator of test performance
Glas, A. S., Lijmer, J. G., Prins, M. H., Bonsel, G. J., & Bossuyt, P. M. M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00177-x · Cited by 2,261
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
Abreu, M. T., Taylor, K. D., Lin, Y.-C., Hang, T., Gaiennie, J., Landers, C. J., Vasiliauskas, E. A., Kam, L. Y., Rojany, M., Papadakis, K. A., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35393 · Cited by 428
Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease
Wang, K., Zhang, H., Kugathasan, S., Annese, V., Bradfield, J. P., Russell, R. K., Sleiman, P. M. A., Imielinski, M., Glessner, J., Hou, C., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.01.026 · Cited by 291
Cited by
Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases
Rieder, F., Fiocchi, C., & Rogler, G. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.047 · Cited by 529
Crohn's disease complicated by strictures: a systematic review
Rieder, F., Zimmermann, E. M., Remzi, F. H., & Sandborn, W. J. (2013) · Gut · doi:10.1136/gutjnl-2012-304353 · Cited by 513
Cleynen, I., González, J. R., Figueroa, C., Franke, A., McGovern, D., Bortlík, M., Crusius, B. J. A., Vecchi, M., Artieda, M., Szczypiorska, M., et al. (2013) · Gut · doi:10.1136/gutjnl-2011-300777 · Cited by 271
Rieder, F., Latella, G., Magro, F., Yuksel, E. S., Higgins, P. D. R., Di Sabatino, A., de Bruyn, J. R., Rimola, J., Brito, J., Bettenworth, D., et al. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw055 · Cited by 261
Self-citationAdler, J., & Higgins, P. D. R. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.264
Self-citation
Metadata
- Authors
- Adler, J., Rangwalla, S. C., Dwamena, B. A., & Higgins, P. D.
- Venue
- American Journal of Gastroenterology
- Published
- 2011-04
- Volume
- 106
- Issue
- 4
- Pages
- 699-712
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2101856875
- Cited by
- 198
- References
- 5
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.